In February 2013, the University of Texas MD Anderson Cancer Center will begin a research program that will initially focus on eight types of cancer. The Moon Shots Program will create six teams of scientists and clinicians to work on projects to develop tests, drugs and policies. Unlike the past, the teams will share infrastructure […]
This month, 10 major drug firms announced their participation in TransCelerate BioPharma, the largest-ever collaboration to speed up drug development. Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche’s Genentech and Sanofi will pool funds and personnel for TransCelerate projects, which will initially focus on five projects for streamlining clinical […]
Despite Congress having passed a continuing resolution to maintain federal agencies’ budgets through the first half of fiscal 2013 (see IBO 8/15/12), the American Association for the Advancement of Science (AAAS) estimates that sequestration could result in a federal R&D budget cut of $57.5 billion, or 8.4%, through 2017. Budgets for nondefense R&D at science […]
La Jolla, CA 9/17/12—Synthetic Genomics (SGI), which is focused on developing genomic solutions for global challenges, has purchased three families of patents and patent applications from Febit Holding, including the know-how, equipment and technical support for implementation. The intellectual property is related to synthetic genomic technologies with the potential to reduce the cost of DNA […]
Aarhus, Denmark 9/3/12—CLC bio, a developer of software for next-generation sequencing, has acquired Molegro for an undisclosed amount. Molegro provides software for molecular docking, including the prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor and determination of molecule similarity. CLC bio stated that the acquisition supported its strategy […]
Bruker Adds to In Vivo Imaging Offerings Rochester, NY and Billerica, MA 9/21/12—Bruker has entered into an agreement to purchase the preclinical in vivo imaging equipment product portfolio and related assets of Carestream’s Molecular Imaging business. The purchase price was not disclosed. The majority of employees at the business will be offered the opportunity to […]
San Diego, CA 9/19/12—Illumina has acquired BlueGnome for an undisclosed amount. UK-based BlueGnome provides solutions for the screening of genetic abnormalities associated with developmental delay, cancer and infertility. Products include the 24sure pre-implantation genetic screening test for in vitro fertilization (IVF) and CytoChip for genetic-abnormalities testing associated with developmental delay or complex leukemias. “The BlueGnome […]
The second of IBO’s biannual new laboratory roundup focuses on new academic and environmental labs, along with companies expanding their lab presence in Europe. In addition, the table on page 3 highlights plans for new CRO, pharmaceutical and semiconductor labs. Three major chemical firms have recently announced labs in Europe. Dutch chemical company Royal DSM […]
A trend among major analytical instrument and lab product companies is the expansion into clinical diagnostic markets, both regulated products and, in the US, services based on laboratory developed tests (LDTs). Clinical diagnostics is a fast-growing market, with multiple opportunities due to the use of new research technologies for diagnostics, growth in emerging markets and […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
